SEC Form 4 · accession 0001193125-26-402936
Hemab Therapeutics Holdings, Inc. · COAG
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Keli Walbert
Director
Period of report
Sep 24, 2026
Accepted (ET)
Sep 25, 2026 · 4:45 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0002114044
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $35.72 | Sep 24, 2026 | A | 36,000 | A | — | Sep 23, 2036 | Common Stock | 36,000 | 36,000 | D |
Explanation of responses
- F1This option was granted on September 24, 2026. The shares underlying the option are scheduled to vest over three years in equal monthly installments from September 24, 2026 through September 24, 2029, subject to continuous service.